Abstract
Animal models are important experimental tools for investigating the molecular mechanisms, environmental and genetic susceptibilities underlying the development of thrombotic microangiopathies. Large mammal, small animal models, knockout, transgenic and conditional knockout mouse models are available to investigate haemolytic uraemic syndrome, thrombotic thrombocytopenic purpura and vascular endothelial growth factor-associated thrombotic microangiopathy. These models have shown that it is possible to model the human conditions. However, differences in human and rodent physiology mean that caution is required when interpreting the findings. These models offer realistic prospects for identifying and testing novel therapeutic strategies in a range of thrombotic microangiopathies prior to human trials.
References
1.
Nangaku M, Nishi H, Fujita T: Pathogenesis and prognosis of thrombotic microangiopathy. Clin Exp Nephrol 2007;11:107–114.
[PubMed]
2.
Kavanagh D, Richards A, Atkinson J: Complement regulatory genes and hemolytic uremic syndromes. Annu Rev Med 2008;59: 293–309.
[PubMed]
3.
Tsai HM: Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med 2006;57:419–436.
[PubMed]
4.
Siegler RL, Obrig TG, Pysher TJ, Tesh VL, Denkers ND, Taylor FB: Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome. Pediatr Nephrol 2003;18:92–96.
[PubMed]
5.
Keepers TR, Psotka MA, Gross LK, Obrig TG: A murine model of Hus: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease. J Am Soc Nephrol 2006;17:3404–3414.
[PubMed]
6.
Paixao-Cavalcante D, Botto M, Cook HT, Pickering MC: Shiga toxin-2 results in renal tubular injury but not thrombotic microangiopathy in heterozygous factor H-deficient mice. Clin Exp Immunol 2009;155:339–347.
[PubMed]
7.
Nangaku M, Alpers CE, Pippin J, Shankland SJ, Adler S, Kurokawa K, Couser WG, Johnson RJ: A new model of renal microvascular endothelial injury. Kidney Int 1997;52:182–194.
[PubMed]
8.
Ren G, Hack BK, Minto AW, Cunningham PN, Alexander JJ, Haas M, Quigg RJ: A complement-dependent model of thrombotic thrombocytopenic purpura induced by antibodies reactive with endothelial cells. Clin Immunol 2002;103:43–53.
[PubMed]
9.
Hashimoto K, Tabata N, Fujisawa R, Matsumura H, Miyazawa M: Induction of microthrombotic thrombocytopenia in normal mice by transferring a platelet-reactive, monoclonal anti-gp70 autoantibody established from MRL/lpr mice: an autoimmune model of thrombotic thrombocytopenic purpura. Clin Exp Immunol 2000;119:47–56.
[PubMed]
10.
Pickering MC, Cook HT, Warren J, Bygrave AE, Moss J, Walport MJ, Botto M: Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 2002;31:424–428.
[PubMed]
11.
Pickering MC, de Jorge EG, Martinez-Barricarte R, Recalde S, Garcia-Layana A, Rose KL, Moss J, Walport MJ, Cook HT, de Cordoba SR, Botto M: Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 2007;204:1249–1256.
[PubMed]
12.
Ferreira VP, Herbert AP, Cortes C, McKee KA, Blaum BS, Esswein ST, Uhrin D, Barlow PN, Pangburn MK, Kavanagh D: The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol 2009;182:7009–7018.
[PubMed]
13.
Pickering MC, Cook HT: Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol 2008;151:210–230.
[PubMed]
14.
de Jorge EG, Paixao-Cavalcante D, Rose KL, Cook HT, Botto M, Pickering MC: C5 activation is required for the development of atypical haemolytic uraemic syndrome in CFH-/-FH delta 16–20 mice. 22nd International Complement Workshop, Basel. Mol Immunol 2008;45:4100.
15.
Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb CB, Desch KC, Zhang W, Tsai HM, Wagner DD, Ginsburg D: Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005;115:2752–2761.
[PubMed]
16.
Banno F, Kokame K, Okuda T, Honda S, Miyata S, Kato H, Tomiyama Y, Miyata T: Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood 2006;107:3161–3166.
[PubMed]
17.
Chauhan AK, Motto DG, Lamb CB, Bergmeier W, Dockal M, Plaimauer B, Scheiflinger F, Ginsburg D, Wagner DD: Systemic antithrombotic effects of ADAMTS13. J Exp Med 2006;203:767–776.
[PubMed]
18.
Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111:707–716.
[PubMed]
19.
Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129–1136.
[PubMed]
20.
Mestas J, Hughes CC: Of mice and not men: differences between mouse and human immunology. J Immunol 2004;172:2731–2738.
[PubMed]
© 2009 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2009
You do not currently have access to this content.
